Report Company Directory

ARQIT QUANTUM INC

• Arqit selected to join Vodafone’s innovation centre Tomorrow Street: Scaleup X programme to explore new business opportunities by GlobeNewsWire
• Arqit launches quantum-safe SKA Edge Controller to secure deployed military operations by GlobeNewsWire
• Arqit Joins Oracle Defense Ecosystem by GlobeNewsWire
• Arqit acquires Ampliphae’s technology IP, enhancing its global encryption portfolio by GlobeNewsWire
• Arqit Quantum Inc. Announces Financial Results for First Half of Fiscal Year 2025 by GlobeNewsWire
• Arqit Quantum Inc. Sets First Half 2025 Conference Call for Thursday, May 22, 2025 at 11:00 a.m. ET by GlobeNewsWire
• Arqit, in collaboration with Equus and Intel, demonstrates a world-first Quantum-Safe CSfC-Compliant MACP Architecture for Classified Mobile Communications by GlobeNewsWire
• Arqit delivers quantum-safe protection enhanced by confidential computing by GlobeNewsWire
• Arqit appoints new Chief Technology Officer to drive innovation and growth by GlobeNewsWire
• RSG purchases test and integration license from Arqit to deliver quantum-secure networks and prepare for commercial-scale deployment by GlobeNewsWire

ArQule Inc.

• ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting by BusinessWire
• ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting by BusinessWire
• ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019 by BusinessWire
• ARQULE INCO. reduces its risk exposure and slightly improves to Neutral by TheScreener
• ArQule Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics by BusinessWire
• ArQule Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics by BusinessWire
• ArQule to Report Third Quarter 2019 Financial Results on October 30, 2019 by BusinessWire
•  ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting by BusinessWire
• InsiderInsights Weekly Tables: September 28, 2019 by InsiderInsights.com
• ArQule to Present at the 2019 Cantor Global Healthcare Conference on October 3, 2019 by BusinessWire

ARRAIL GROUP LTD

ARRAS GROUP S.P.A.

Array BioPharma Inc.

• Array Technologies Inc: 1 director by SmartInsider
• Monthly LMI Update Independent Investment Research by Independent Investment Research
• Feasibility Study Results in December to be a Catalyst for this Junior by Fundamental Research
• ARRAY BIOPHARMA INCO. reduces its risk exposure and slightly improves to Neutral by TheScreener
• UAFRS vs As Reported Weekly Highlights - 2018 11 07 by Valens Research
• SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Array Biopharma Inc. of Class Action Lawsuit and Upcoming Deadline – ARRY by BusinessWire
• The Klein Law Firm Reminds Shareholders of a Class Action on Behalf of Array Biopharma Inc. Shareholders and a Lead Plaintiff Deadline of January 22, 2018 by BusinessWire
• ARRY EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Array Biopharma Inc. and a Lead Plaintiff Deadline of January 22, 2018 by BusinessWire
• SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Array BioPharma Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit by BusinessWire
• EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 by BusinessWire